Collectively, our work provides evidence that KIF20A regulates malignant properties and induces chemoresistance in CRC by activating the JAK2/STAT3 signaling pathway, which introduces a novel biomarker for CRC and a therapeutic target for the improvement of chemoresistance in patients with CRC. This evidence concerns the gene STAT3 and colorectal carcinoma.